Home / Publications / Pain Research Forum / Papers of the Week / Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials.
Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials.
Authors
Lipton RB, Blumenfeld A, Jensen CM, Croop R, Thiry A, L'Italien G, Morris BA, Coric V, Goadsby PJ
Abstract
This post-hoc analysis from three phase 3 treatment trials of rimegepant 75 mg – an oral small molecule calcitonin gene-related peptide receptor antagonist for acute and preventive treatment of migraine – assessed efficacy in adults with migraine based on triptan treatment experience.
This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the IASP Privacy Policy. By closing this banner, you agree to the use of cookies.Agree
